Three insights:
1. IDCT is an injectable cell therapy that use progenitor cells — known as Discogenic Cells — to provide a regenerative solution for the treatment of mild to moderate degenerative disc disease.
2. Its biomedically engineered progenitor cells are derived from intervertebral disc tissue and offer a non-invasive approach to treating the condition.
3. IDCT is currently being evaluated in clinical trials in the U.S. and Japan.
More articles on devices:
Colorado health system building orthopedic, sports medicine practice
Aurora Spine posts $3.2M in Q2 revenue: 6 things to know
Dr. Thomas Parisi, patient travel to Mexico for total knee replacement where it costs $18,000 less
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
